Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet,
an Expert Panel was selected according to the framework elements of the National Institutes …

Despite its history as a human teratogen, thalidomide is emerging as a treatment for cancer
and inflammatory diseases. Although the evolution of its clinical application could not have …

The myelodysplastic syndromes (MDSs) are heterogeneous with respect to clinical
characteristics, pathologic features, and cytogenetic abnormalities. This heterogeneity is a …

Background Ineffective erythropoiesis is the hallmark of myelodysplastic syndromes.
Management of the anemia caused by ineffective erythropoiesis is difficult. In patients with …

Venous thromboembolism (VTE) is a frequent and potentially life-threatening complication
associated with hematological and solid tumor malignancies. In patients with cancer, VTE …

Lenalidomide is approved for red blood cell (RBC) transfusion-dependent anemia due to
low or intermediate-1 (int-1) risk myelodysplastic syndromes (MDSs) associated with a …

Over the past 50 years, thalidomide has been a target of active investigation in both
malignant and inflammatory conditions. Although initially developed for its sedative …

Overview T he myelodysplastic syndromes (MDS) represent myeloid clonal hemopathies
with relatively heterogeneous spectrums of presentation. The major clinical problems in …

Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis with
varying degrees of dysplasia and peripheral cytopenias. MDS are driven by structural …

The myelodysplastic syndromes (MDS) are characterized by hemopoietic insufficiency
associated with cytopenias leading to serious morbidity plus the additional risk of leukemic …